San Diego-dependent Viking Therapeutics marked alone as a serious competitor while in the weight loss drug current market in February following revealing promising data from the mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when presented being a weekly injection As well as in Marc… Read More